One-Minute Exercise Snacks and Daytime Glucose in Adults With Type 2 Diabetes
NCT07930065, Not applicable, Completed, Capital University of Physical Education and Sports, China
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | One-Minute Exercise Snacks and Daytime Glucose in Adults With Type 2 Diabetes | ClinicalTrials.gov |
| NCT number | NCT07930065 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Capital University of Physical Education and Sports, China | ClinicalTrials.gov |
| Conditions | Type 2 Diabetes Mellitus | ClinicalTrials.gov |
| Interventions | 1-Minute Exercise Snacks | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Mean Daytime Sensor Glucose (06:00-24:00) | Days 1-2 of each of the four experimental conditions (06:00-24:00 daily), across approximately 4 weeks. | Mean interstitial glucose concentration (mmol/L) measured using a blinded continuous glucose monitoring (CGM) system (FreeStyle Libre Pro). Daytime glucose was defined as the average sensor glucose concentration recorded between 06:00 and 24:00 on each observation day. The primary outcome was calculated as the mean daytime sensor glucose across the two consecutive observation days within each experimental condition (CON, ES4, ES6, and ES8). Glucose measurements were recorded at 15-minute intervals. | ClinicalTrials.gov |
| Secondary | Mean 24-Hour Sensor Glucose | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Mean sensor glucose concentration (mmol/L) measured using blinded continuous glucose monitoring (CGM) from 00:00 to 24:00, averaged across the two observation days of each condition. | ClinicalTrials.gov |
| Secondary | Mean Nighttime Sensor Glucose | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Mean CGM-derived sensor glucose concentration (mmol/L) between 00:00 and 06:00, averaged across the two observation days of each experimental condition. | ClinicalTrials.gov |
| Secondary | Mean Non-Postprandial Daytime Sensor Glucose | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Mean sensor glucose concentration (mmol/L) during the 12 non-postprandial daytime hours, excluding the three designated 2-hour postprandial windows from 06:00 to 24:00, averaged across two observation days per condition. | ClinicalTrials.gov |
| Secondary | Standard Deviation of Sensor Glucose | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Standard deviation (SD) of glucose concentrations (mmol/L) derived from CGM readings during each experimental condition, representing absolute glycemic variability. | ClinicalTrials.gov |
| Secondary | Coefficient of Variation of Sensor Glucose | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Coefficient of variation (CV, %) of CGM-derived glucose, calculated as 100 multiplied by the glucose standard deviation divided by the mean glucose concentration for each condition. | ClinicalTrials.gov |
| Secondary | Mean Amplitude of Glycemic Excursions | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Mean amplitude of glycemic excursions (MAGE, mmol/L) calculated from CGM recordings according to the prespecified Service method to characterize glucose fluctuations. | ClinicalTrials.gov |
| Secondary | Time in Range (3.9-10.0 mmol/L) | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Percentage of valid CGM monitoring time during which sensor glucose concentrations were within the target range of 3.9-10.0 mmol/L. | ClinicalTrials.gov |
| Secondary | Time in Tight Range (3.9-7.8 mmol/L) | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Percentage of valid CGM monitoring time during which sensor glucose concentrations were within the tighter glucose range of 3.9-7.8 mmol/L. | ClinicalTrials.gov |
| Secondary | Time Above Range (>10.0 mmol/L) | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Percentage of valid CGM monitoring time during which sensor glucose concentrations exceeded 10.0 mmol/L. | ClinicalTrials.gov |
| Secondary | Time Below Range (<3.9 mmol/L) | Days 1-2 of each of the four experimental conditions (approximately 4 weeks in total). | Percentage of valid CGM monitoring time during which sensor glucose concentrations were below 3.9 mmol/L. | ClinicalTrials.gov |
| Secondary | Mean Postprandial Sensor Glucose | 0-120 minutes after breakfast, lunch, and dinner on Days 1-2 of each of the four experimental conditions. | Mean CGM-derived glucose concentration (mmol/L) during the 0-120-minute period following the first bite of each meal, evaluated for breakfast, lunch, and dinner. | ClinicalTrials.gov |
| Secondary | Peak Postprandial Sensor Glucose | 0-120 minutes after breakfast, lunch, and dinner on Days 1-2 of each of the four experimental conditions. | Maximum CGM-derived glucose concentration (mmol/L) observed within 120 minutes after the first bite of breakfast, lunch, or dinner. | ClinicalTrials.gov |
| Secondary | Postprandial Incremental Glucose Area Under the Curve | 0-120 minutes after breakfast, lunch, and dinner on Days 1-2 of each of the four experimental conditions. | Incremental glucose area under the curve (iAUC, mmol/L × min) from 0 to 120 minutes after meal initiation, calculated by the trapezoidal method using the mean of the readings at meal initiation and 15 minutes before the meal as baseline. Areas below baseline were excluded. | ClinicalTrials.gov |
| Secondary | Self-Reported Completed Exercise Snacks per Day | Days 1-2 of the ES4, ES6, and ES8 conditions, across approximately 4 weeks. | Mean daily number of prescribed exercise snacks reported as completed in electronic exercise logs, calculated separately for the ES4, ES6, and ES8 conditions. | ClinicalTrials.gov |
| Secondary | Heart-Rate-Verified Exercise Snacks per Day | Days 1-2 of the ES4, ES6, and ES8 conditions, across approximately 4 weeks. | Mean daily number of self-reported exercise snacks verified by synchronized Polar H10 heart-rate records, with matching completion times within ±10 minutes and a heart-rate rise consistent with a 1-minute exercise bout. | ClinicalTrials.gov |
| Secondary | Delivered Exercise Snack Dose per Day | Days 1-2 of the ES4, ES6, and ES8 conditions, across approximately 4 weeks. | Mean daily number of exercise snacks meeting the protocol-defined level-3 verification criteria, requiring heart-rate-confirmed completion and achievement of the prespecified intensity threshold. The count was averaged over the two observation days of each exercise condition. | ClinicalTrials.gov |
| Secondary | Self-Reported Exercise Completion Rate | Days 1-2 of the ES4, ES6, and ES8 conditions, across approximately 4 weeks. | Percentage of prescribed exercise snack sessions reported as completed in the electronic exercise log, calculated separately for each exercise condition. | ClinicalTrials.gov |
| Secondary | Rating of Perceived Exertion During Exercise Snacks | Each prescribed exercise session on Days 1-2 of the ES4, ES6, and ES8 conditions, across approximately 4 weeks. | Perceived exertion recorded after each exercise snack using the Borg CR-10 scale (0-10), with higher scores indicating greater perceived exertion. The prescribed target was 7-9. | ClinicalTrials.gov |
| Secondary | Peak Heart Rate During Exercise Snacks | Each prescribed exercise session on Days 1-2 of the ES4, ES6, and ES8 conditions, across approximately 4 weeks. | Maximum heart rate (beats per minute) recorded using a Polar H10 chest strap during each exercise snack. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)